Ascendis Pharma to raise capital with convertible notes

Biotech firm Ascendis Pharma intends to offer convertible notes for a sum of USD 500m.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by ANDREAS LØNSTRUP, translated by daniel pedersen

Danish biotech firm Ascendis Pharma, which is listed in the US, wants to raise USD 500m by offering convertible notes, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading